Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y2R0

UPID:
COA3_HUMAN

ALTERNATIVE NAMES:
Coiled-coil domain-containing protein 56; Mitochondrial translation regulation assembly intermediate of cytochrome c oxidase protein of 12 kDa

ALTERNATIVE UPACC:
Q9Y2R0; A8K498

BACKGROUND:
The Cytochrome c oxidase assembly factor 3 homolog, mitochondrial, known alternatively as Mitochondrial translation regulation assembly intermediate of cytochrome c oxidase protein of 12 kDa, is integral to mitochondrial function. It regulates both the translation of mitochondrial encoded components and the assembly of nuclear-encoded components into the mitochondrion. Its role is critical for the assembly of mitochondrial respiratory chain complex IV.

THERAPEUTIC SIGNIFICANCE:
Associated with Mitochondrial complex IV deficiency, nuclear type 14, characterized by a spectrum of neurological and metabolic abnormalities, the protein's study offers a promising avenue for therapeutic intervention. By elucidating the mechanisms through which this protein functions, researchers can pave the way for novel treatments aimed at mitigating the impacts of this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.